Notes to SEFA
Title: Subrecipients
Accounting Policies: Basis of presentation - The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Bloodworks Northwest (the Organization or Bloodworks) under programs of the federal government for the year ended June 30, 2023. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principls, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of Bloodworks, it is not intended to and does not present the financial position, changes in net assets or cash flows of Bloodworks.
Accounting policies - Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. Pass-through entity identifying numbers are presented where available.
De Minimis Rate Used: N
Rate Explanation: Bloodworks did not elect to use the 10 percent de minimis cost basis. Bloodworks uses the Federally Negotiated indirect rate for the period covered, for direct costs tha are not excluded.
Of the federal expenditures presented in the Schedule, under Assistance Listing No. 93.839, Blood Diseases and Resources Research, Bloodworks provided federal awards to subrecipients. See the Notes to the SEFA for chart/table.
Title: Subrecipients
Accounting Policies: Basis of presentation - The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Bloodworks Northwest (the Organization or Bloodworks) under programs of the federal government for the year ended June 30, 2023. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principls, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of Bloodworks, it is not intended to and does not present the financial position, changes in net assets or cash flows of Bloodworks.
Accounting policies - Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. Pass-through entity identifying numbers are presented where available.
De Minimis Rate Used: N
Rate Explanation: Bloodworks did not elect to use the 10 percent de minimis cost basis. Bloodworks uses the Federally Negotiated indirect rate for the period covered, for direct costs tha are not excluded.
Of the federal expenditures presented in the Schedule, under Assistance Listing No. 12.420, Military Medical Research and Development, Bloodworks provided federal awards to one recipient. See the Notes to the SEFA for chart/table.